Extract
Chronic pulmonary hypertension shares abnormalities found in chronic left heart failure and chronic respiratory failure, in which rehabilitation has been proposed [1, 2]. In a recent statement endorsed by the European Respiratory Society, Grünig et al. [3] proposed an exhaustive review of available data on rehabilitation in the setting of chronic pulmonary hypertension. The main messages proposed are “Specialised exercise training in patients with pulmonary hypertension appears to be effective, cost-efficient and safe.”
Abstract
Rehabilitation appears to be beneficial in PAH patients, but more research is needed before increasing the level of evidence for recommendations. http://bit.ly/33zutuZ
Acknowledgements
The authors thank Deirdre Epinat (Laniel Traduction SA, Saint-Etienne, 42000, France) for English editing.
Footnotes
The FONCE-HTAP investigators are as follows. Steering committee: Laurent Bertoletti (Chairman), Hélène Bouvaist, Bruno Degano, Christophe Pison. Coordination centre: Laurent Bertoletti, Souad Bezzeghoud, Carine Labruyere. Investigators: Saint-Etienne: Laurent Bertoletti (PI), Stéphanie Chomette Ballereau, Sandrine Accassat, Elodie De Magalhaes, David Hupin, Pierre Labeix, Pierre Croisille. Grenoble: Christophe Pison (PI), Hélène Bouvaist, Bruno Degano, Marianne Noirclerc. Clermont-Ferrand: Claire Dauphin (PI), Romain Tresorier, Fréderic Costes. Brest: Cécile Tromeur (PI), Francis Couturaud, Christophe Gut-Gobert. Lyon: Ségolène Turquier (PI), Vincent Cottin, Julie Traclet, Sophie Lamoureux, Clément Deudon.Strasbourg: Irina Enache (PI), Marianne Riou, Mathieu Canuet, Armelle Schuller, Evelyne Lonsdorfer. Besançon: Marie-France Seronde (PI), Pauline Marie Roux. Montpellier: Arnaud Bourdin (PI), Clément Boissin, Anne-Sophie Gamez-Dubuis. Paris: David Montani (PI), Gilles Garcia, Pierantonio Laveneziana, Antoine Guerder, Marc Humbert.
Conflict of interest: L. Bertoletti has nothing to disclose.
Conflict of interest: H. Bouvaist reports grants and non-financial support from GSK and MSD, and personal fees and non-financial support from Actelion, outside the submitted work.
Conflict of interest: C. Tromeur has nothing to disclose.
Conflict of interest: S. Bezzeghoud has nothing to disclose.
Conflict of interest: C. Dauphin has nothing to disclose.
Conflict of interest: I. Enache has nothing to disclose.
Conflict of interest: A. Bourdin reports grants, personal fees, non-financial support and other from AstraZeneca, GSK and Boehringer Ingelheim, personal fees and other from Chiesi, personal fees, non-financial support and other from Novartis, Actelion and Sanofi Regeneron, and other funding from United Therapeutics, Vertex, Galapagos, Biogen and BTG, outside the submitted work.
Conflict of interest: M-F. Seronde has nothing to disclose.
Conflict of interest: D. Montani reports grants and personal fees from Actelion and Bayer, and personal fees from GSK, MSD and Pfizer, outside the submitted work.
Conflict of interest: S. Turquier has nothing to disclose.
Conflict of interest: C. Pison has nothing to disclose.
Support statement: Support was received from the Ministère des Affaires Sociales et de la Santé, grant PHRCi 2013, and AIRE (AIde à la REcherche médicale de proximité; https://aire-loire.fr/). Funding information for this article has been deposited with the Crossref Funder Registry.
- Received August 5, 2019.
- Accepted August 7, 2019.
- Copyright ©ERS 2019
LIBRARY USERS
Log in through your institution
Purchase access
